09:58 AM EST - MethylGene Inc. : provided a clinical update on MGCD290, the novel, orally available antifungal agent. Clinical data from four Phase I safety trials of MGCD290 will be presented at the 2012 IDWeek(TM) meeting, to be held in San Diego, California from October 17-21. IDWeek(TM) is a joint meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). MethylGene Inc.
shares T.MYG are trading unchanged at $0.23.
